TWI482773B - 氮呯并〔４，５－ｂ〕吲哚及使用方法 - Google Patents

氮呯并〔４，５－ｂ〕吲哚及使用方法 Download PDF

Info

Publication number
TWI482773B
TWI482773B TW098137049A TW98137049A TWI482773B TW I482773 B TWI482773 B TW I482773B TW 098137049 A TW098137049 A TW 098137049A TW 98137049 A TW98137049 A TW 98137049A TW I482773 B TWI482773 B TW I482773B
Authority
TW
Taiwan
Prior art keywords
group
substituted
unsubstituted
compound
salt
Prior art date
Application number
TW098137049A
Other languages
English (en)
Chinese (zh)
Other versions
TW201022270A (en
Inventor
David T Hung
Andrew Asher Protter
Rajendra Parasmal Jain
Sarvajit Chakravarty
Marco Giorgetti
Original Assignee
Medivation Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medivation Technologies Inc filed Critical Medivation Technologies Inc
Publication of TW201022270A publication Critical patent/TW201022270A/zh
Application granted granted Critical
Publication of TWI482773B publication Critical patent/TWI482773B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
TW098137049A 2008-10-31 2009-10-30 氮呯并〔４，５－ｂ〕吲哚及使用方法 TWI482773B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11052708P 2008-10-31 2008-10-31
US17396509P 2009-04-29 2009-04-29
US24525709P 2009-09-23 2009-09-23

Publications (2)

Publication Number Publication Date
TW201022270A TW201022270A (en) 2010-06-16
TWI482773B true TWI482773B (zh) 2015-05-01

Family

ID=42129314

Family Applications (1)

Application Number Title Priority Date Filing Date
TW098137049A TWI482773B (zh) 2008-10-31 2009-10-30 氮呯并〔４，５－ｂ〕吲哚及使用方法

Country Status (10)

Country Link
US (4) US8569287B2 (cg-RX-API-DMAC7.html)
EP (1) EP2348847A4 (cg-RX-API-DMAC7.html)
JP (1) JP5551708B2 (cg-RX-API-DMAC7.html)
CN (1) CN102316732B (cg-RX-API-DMAC7.html)
AR (1) AR073924A1 (cg-RX-API-DMAC7.html)
AU (1) AU2009308708B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0921798A2 (cg-RX-API-DMAC7.html)
CA (1) CA2742322A1 (cg-RX-API-DMAC7.html)
TW (1) TWI482773B (cg-RX-API-DMAC7.html)
WO (1) WO2010051503A1 (cg-RX-API-DMAC7.html)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2007139634A (ru) 2007-10-25 2009-04-27 Сергей Олегович Бачурин (RU) Новые тиазол-, триазол- или оксадиазол-содержащие тетрациклические соединения
RU2544856C2 (ru) * 2008-01-25 2015-03-20 Сергей Олегович Бачурин НОВЫЕ ПРОИЗВОДНЫЕ 2,3,4,5-ТЕТРАГИДРО-1-ПИРИДО[4,3-b]ИНДОЛА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
US8338447B2 (en) 2008-03-24 2012-12-25 Medivation Technologies, Inc. Pyrido[3,4-B]indoles and methods of use
CN102046625B (zh) 2008-03-24 2015-04-08 梅迪维新技术公司 桥连杂环化合物及其使用方法
EP2348847A4 (en) 2008-10-31 2012-05-23 Medivation Technologies Inc AZEPINO [4, 5-B] INDOLE AND USE PROCESS
CA2742320A1 (en) 2008-10-31 2010-05-06 Medivation Technologies, Inc. Pyrido[4,3-b]indoles containing rigid moieties
WO2010051561A1 (en) * 2008-11-03 2010-05-06 Chemocentryx, Inc. Compounds for the treatment of osteoporosis and cancers
US9162980B2 (en) 2009-01-09 2015-10-20 Board Of Regents Of The University Of Texas System Anti-depression compounds
US9962368B2 (en) 2009-01-09 2018-05-08 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
WO2010081115A1 (en) 2009-01-09 2010-07-15 University Of Texas Southwestern Medical Center Pro-neurogenic compounds
US8362277B2 (en) 2009-01-09 2013-01-29 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
AU2010214101A1 (en) * 2009-02-11 2011-09-01 Sunovion Pharmaceuticals Inc. Histamine H3 inverse agonists and antagonists and methods of use thereof
CA2760541A1 (en) 2009-04-29 2010-11-04 Medivation Technologies, Inc. Pyrido[4,3-b] indoles and methods of use
US8741919B2 (en) 2009-04-29 2014-06-03 Medivation Technologies, Inc. Pyrido[4,3-B]indoles and methods of use
MX2012002898A (es) * 2009-09-11 2012-04-02 Sunovion Pharmaceuticals Inc Agonistas y antagonistas inversos de histamina h3 y metodos de uso para los mismos.
CN102724875B (zh) 2009-09-23 2015-05-27 梅迪维新技术公司 吡啶并[3,4-b]吲哚化合物及其使用方法
CN102711466A (zh) 2009-09-23 2012-10-03 梅迪维新技术公司 桥连杂环化合物及其使用方法
BR112012006640A2 (pt) 2009-09-23 2019-09-24 Medivation Technologies Inc composto, composição farmacêutica, método de tratamento de um distúrbio cognitivo, distúrbiopsocótico, distúrbio mediado por neurotransmissor ou um distúrbio neuronal e kit
US9040519B2 (en) 2010-02-18 2015-05-26 Medivation Technologies, Inc. Fused tetracyclic pyrido [4,3-B] indole and pyrido [3,4-B] indole derivatives and methods of use
WO2011103460A1 (en) 2010-02-18 2011-08-25 Medivation Technologies, Inc. Fused tetracyclic pyrido[4,3-b]indole and pyrido[3,4-b]ondole derivatives and methods of use
US9034865B2 (en) 2010-02-18 2015-05-19 Medivation Technologies, Inc. Pyrido [4,3-B] indole and pyrido [3,4-B] indole derivatives and methods of use
WO2011103430A1 (en) 2010-02-19 2011-08-25 Medivation Technologies, Inc. Pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use
EP2590647B1 (en) 2010-07-07 2017-11-08 Board of Regents of the University of Texas System Pro-neurogenic compounds
WO2012112963A1 (en) 2011-02-18 2012-08-23 Medivation Technologies, Inc. Compounds and methods for treatment of hypertension
WO2012112964A2 (en) * 2011-02-18 2012-08-23 Medivation Technologies, Inc. PYRIDO[4,3-b]INDOLE AND PYRIDO[3,4-b]INDOLE DERIVATIVES AND METHODS OF USE
JP2014505737A (ja) * 2011-02-18 2014-03-06 メディベイション テクノロジーズ， インコーポレイテッド 糖尿病を処置する化合物および方法
WO2012112965A1 (en) * 2011-02-18 2012-08-23 Medivation Technologies, Inc. Compounds and methods of treating diabetes
WO2014031165A1 (en) * 2012-08-22 2014-02-27 Medivation Technologies, Inc. Compounds and methods of treating diabetes
CA2882826A1 (en) 2012-08-24 2014-02-27 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
EP2746258A1 (en) 2012-12-21 2014-06-25 Basf Se Substituted [1,2,4]triazole and imidazole compounds
EP2746257A1 (en) 2012-12-21 2014-06-25 Basf Se Substituted [1,2,4]triazole and imidazole compounds
WO2015070237A1 (en) 2013-11-11 2015-05-14 Board Of Regents Of The University Of Texas System Neuroprotective chemicals and methods for identifying and using same
WO2015070234A2 (en) 2013-11-11 2015-05-14 Board Of Regents Of The University Of Texas System Neuroprotective compounds and use thereof
CN105037298B (zh) * 2015-07-08 2017-09-26 华南理工大学 一种含三氟甲基取代连续季碳中心环氧丙烷衍生物及合成方法
EP3519816A4 (en) 2016-09-29 2020-05-06 The Regents of the University of California Compounds for increasing neural plasticity
WO2020165802A1 (en) * 2019-02-13 2020-08-20 Centre For Addiction And Mental Health Compositions and methods relating to use of agonists of alpha5-containing gabaa receptors
BR112021016620A2 (pt) 2019-02-27 2021-11-03 Univ California Azepino-indóis e outros heterociclos para o tratamento de distúrbios cerebrais
CN110526935A (zh) * 2019-09-04 2019-12-03 天津理工大学 一种双硼氮杂菲及其衍生物的合成方法
TW202333668A (zh) 2021-12-15 2023-09-01 美商德利克斯醫療公司 經苯氧基及苄氧基取代之精神成形素(psychoplastogen)及其用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020077318A1 (en) * 2000-09-20 2002-06-20 Frank Kristine E. Substituted azepino[4,5b] indoline derivatives

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH445508A (de) * 1964-12-03 1967-10-31 Geigy Ag J R Verfahren zur Herstellung von neuen Indolderivaten
FR1524830A (fr) 1966-05-31 1968-05-10 Geigy Ag J R Nouveaux dérivés de l'indole et leur préparation
US3525750A (en) * 1966-05-31 1970-08-25 Geigy Chem Corp 1,2,3,4,5,6-hexahydro-azepino(4,5-b) indole derivatives
JPS63163347A (ja) 1986-12-25 1988-07-06 Konica Corp 有機着色物質の光褪色防止方法
US4754038A (en) * 1987-02-26 1988-06-28 American Home Products Corporation Carboline histamine H1 antagonists
FR2663935A1 (fr) * 1990-06-27 1992-01-03 Adir Nouveaux 1,2,3,4,5,6-hexahydroazepino [4,5-b] indoles et 1,2,3,4-tetrahydrobethacarbolines, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent.
RU2106864C1 (ru) * 1995-10-23 1998-03-20 Николай Серафимович Зефиров Средство для лечения болезни альцгеймера
TW470745B (en) 1996-05-23 2002-01-01 Janssen Pharmaceutica Nv Hexahydro-pyrido[4,3-b]indole derivatives
US6140337A (en) 1997-12-23 2000-10-31 Schering Corporation Methods for the treatment of mental disorders
MY122278A (en) 1999-07-19 2006-04-29 Upjohn Co 1,2,3,4,5,6-hexahydroazepino[4,5-b]indoles containing arylsulfones at the 9-position
FR2817257B1 (fr) * 2000-11-30 2009-03-20 Sanofi Synthelabo Cyclohexyl(alkyl)-propanolamines, leur preparation et compositions pharmaceutiques en contenant
TWI329111B (en) * 2002-05-24 2010-08-21 X Ceptor Therapeutics Inc Azepinoindole and pyridoindole derivatives as pharmaceutical agents
US7736889B2 (en) 2003-06-10 2010-06-15 The United States Of America As Represented By The Secretary Of The Navy Fluidic force discrimination
JP4679517B2 (ja) * 2003-07-23 2011-04-27 エグゼリクシス， インコーポレイテッド 薬剤としてのアゼピン誘導体
RU2283108C2 (ru) 2003-12-08 2006-09-10 Сергей Олегович Бачурин ГЕРОПРОТЕКТОР НА ОСНОВЕ ГИДРИРОВАННЫХ ПИРИДО(4,3-b) ИНДОЛОВ (ВАРИАНТЫ), ФАРМАКОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ И СПОСОБ ЕГО ПРИМЕНЕНИЯ
US20070179174A1 (en) 2003-12-08 2007-08-02 Bachurin Sergei O Methods and compositions for slowing aging
CN101175754A (zh) 2005-03-22 2008-05-07 阿斯利康(瑞典)有限公司 用作CB1受体配体的新四氢-1H-吡啶并[4,3-b]吲哚衍生物
KR20080034171A (ko) 2005-07-28 2008-04-18 브리스톨-마이어스 스큅 컴퍼니 세로토닌 수용체 효능제 및 길항제로서의 치환된테트라히드로-1ｈ-피리도[4,3,ｂ]인돌
WO2007041697A2 (en) 2005-10-04 2007-04-12 Medivation, Inc. Hydrogenated pyrido-indole compounds for the treatment of huntington ' s disease
RU2338537C2 (ru) 2006-01-25 2008-11-20 Сергей Олегович Бачурин СРЕДСТВО ДЛЯ ЛЕЧЕНИЯ ШИЗОФРЕНИИ НА ОСНОВЕ ГИДРИРОВАННЫХ ПИРИДО(4,3-b)ИНДОЛОВ (ВАРИАНТЫ), ФАРМАКОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ И СПОСОБ ЕГО ПРИМЕНЕНИЯ
RU2317989C1 (ru) 2006-08-24 2008-02-27 Андрей Александрович Иващенко ЗАМЕЩЕННЫЕ АЗЕПИНО[4,3-b]ИНДОЛЫ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СПОСОБ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ
AU2007297539A1 (en) 2006-09-20 2008-03-27 Medivation Neurology, Inc. Methods and compositions for treating amyotrophic lateral sclerosis (ALS)
EP2066322A2 (en) 2006-09-20 2009-06-10 Medivation Neurology, Inc. Hydrogenated pyrido [4,3-b] indoles such as dimebon for treating canine cognitive dysfunction syndrome
RU2009120048A (ru) 2006-10-27 2010-12-10 Медивэйшн Ньюролоджи, Инк. (Us) Способы и комбинированные средства для лечения болезни альцгеймера
RU2329044C1 (ru) 2006-11-16 2008-07-20 Андрей Александрович Иващенко Лиганды 5-ht6 рецепторов, фармацевтическая композиция, способ ее получения и лекарственное средство
RU2334514C1 (ru) 2006-12-01 2008-09-27 Институт физиологически активных веществ Российской Академии наук СРЕДСТВО ДЛЯ УЛУЧШЕНИЯ КОГНИТИВНЫХ ФУНКЦИЙ И ПАМЯТИ НА ОСНОВЕ ГИДРИРОВАННЫХ ПИРИДО (4,3-b) ИНДОЛОВ (ВАРИАНТЫ), ФАРМАКОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ И СПОСОБ ЕГО ПРИМЕНЕНИЯ
RU2340342C2 (ru) 2006-12-07 2008-12-10 Сергей Олегович Бачурин СРЕДСТВО ДЛЯ ЛЕЧЕНИЯ ОСТРЫХ И ХРОНИЧЕСКИХ НАРУШЕНИЙ МОЗГОВОГО КРОВООБРАЩЕНИЯ, В ТОМ ЧИСЛЕ ИНСУЛЬТА, НА ОСНОВЕ ГИДРИРОВАННЫХ ПИРИДО[4,3-b]ИНДОЛОВ (ВАРИАНТЫ), ФАРМАКОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ И СПОСОБ ЕГО ПРИМЕНЕНИЯ
RU2338745C1 (ru) 2007-03-21 2008-11-20 Андрей Александрович Иващенко ЗАМЕЩЕННЫЕ 2,3,4,5-ТЕТРАГИДРО-1Н-ПИРИДО[4,3-b]ИНДОЛЫ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ
CA2683453C (en) * 2007-04-05 2013-06-11 Alla Chem, Llc Substituted 2,3,4,5-tetrahydro-1h-pyrido[4,3-.beta.]indoles, methods for the production and use thereof
RU2339637C1 (ru) 2007-04-05 2008-11-27 Андрей Александрович Иващенко Блокаторы гистаминного рецептора для фармацевтических композиций, обладающих противоаллергическим и аутоиммунным действием
US20100178277A1 (en) 2007-05-25 2010-07-15 Medivation Neurology, Inc. Methods and compositions for stimulating cells
RU2338533C1 (ru) 2007-06-28 2008-11-20 Сергей Олегович Бачурин СРЕДСТВО, ОБЛАДАЮЩЕЕ АНКСИОЛИТИЧЕСКИМ ДЕЙСТВИЕМ, НА ОСНОВЕ ГИДРИРОВАННЫХ ПИРИДО(4,3-b)ИНДОЛОВ (ВАРИАНТЫ), ФАРМАКОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ И СПОСОБ ЕГО ПРИМЕНЕНИЯ
MX2010001218A (es) 2007-08-01 2010-04-07 Medivation Neurology Inc Metodos y composiciones para tratamiento contra esquizofrenia mediante uso de terapia combinada de agentes antipsicoticos.
EP2189048A1 (en) 2007-09-14 2010-05-26 Services Pétroliers Schlumberger Particle acceleration devices and methods thereof
WO2009039420A1 (en) 2007-09-21 2009-03-26 Medivation Neurology, Inc. Methods and compositions for treating neuronal death mediated ocular diseases
RU2007139634A (ru) 2007-10-25 2009-04-27 Сергей Олегович Бачурин (RU) Новые тиазол-, триазол- или оксадиазол-содержащие тетрациклические соединения
WO2009082268A2 (ru) 2007-12-21 2009-07-02 Alla Chem, Llc ЛИГАНДЫ α-АДРЕНОЦЕПТОРОВ, ДОПАМИНОВЫХ, ГИСТАМИНОВЫХ, ИМИДАЗОЛИНОВЫХ И СЕРОТОНИНОВЫХ РЕЦЕПТОРОВ И ИХ ПРИМЕНЕНИЕ
KR101600634B1 (ko) 2007-12-28 2016-03-07 미쓰비시 타나베 파마 코퍼레이션 항암제
RU2544856C2 (ru) 2008-01-25 2015-03-20 Сергей Олегович Бачурин НОВЫЕ ПРОИЗВОДНЫЕ 2,3,4,5-ТЕТРАГИДРО-1-ПИРИДО[4,3-b]ИНДОЛА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
WO2009111540A1 (en) 2008-03-04 2009-09-11 Medivation Neurology, Inc. Methods for preparing pyridylethyl-substituted carbolines
CN102046625B (zh) 2008-03-24 2015-04-08 梅迪维新技术公司 桥连杂环化合物及其使用方法
US8338447B2 (en) 2008-03-24 2012-12-25 Medivation Technologies, Inc. Pyrido[3,4-B]indoles and methods of use
WO2009135091A1 (en) 2008-04-30 2009-11-05 Medivation Technologies, Inc. Use of asenapine and related compounds for the treatment of neuronal or non-neuronal diseases or conditions
US20100029706A1 (en) 2008-07-30 2010-02-04 Edison Parmaceuticals, Inc. a Delaware Corporation HYDROGENATED PYRIDO[4,3-b]INDOLES FOR THE TREATMENT OF OXIDATIVE STRESS
AR073701A1 (es) 2008-09-29 2010-11-24 Abbott Lab Derivados de indol y de indolicina, metodos para su preparacion, una composicion farmaceutica que los comprende y su uso en el tratamiento de enfermedades neurodegenerativas.
US9625475B2 (en) 2008-09-29 2017-04-18 Abbvie Inc. Indole and indoline derivatives and methods of use thereof
CA2742320A1 (en) 2008-10-31 2010-05-06 Medivation Technologies, Inc. Pyrido[4,3-b]indoles containing rigid moieties
EP2348847A4 (en) 2008-10-31 2012-05-23 Medivation Technologies Inc AZEPINO [4, 5-B] INDOLE AND USE PROCESS
WO2010081115A1 (en) 2009-01-09 2010-07-15 University Of Texas Southwestern Medical Center Pro-neurogenic compounds
US8362277B2 (en) 2009-01-09 2013-01-29 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
US9962368B2 (en) 2009-01-09 2018-05-08 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
CA2760541A1 (en) 2009-04-29 2010-11-04 Medivation Technologies, Inc. Pyrido[4,3-b] indoles and methods of use
US8741919B2 (en) * 2009-04-29 2014-06-03 Medivation Technologies, Inc. Pyrido[4,3-B]indoles and methods of use
WO2011008312A2 (en) 2009-07-14 2011-01-20 Abbott Laboratories Indole and indoline derivatives and methods of use thereof
WO2011014695A1 (en) 2009-07-29 2011-02-03 Medivation Technologies, Inc. New 2,3,4,5-tetrahydro-1h-pyrido[4,3-b] indoles and methods of use
CN102724875B (zh) 2009-09-23 2015-05-27 梅迪维新技术公司 吡啶并[3,4-b]吲哚化合物及其使用方法
CN102711466A (zh) 2009-09-23 2012-10-03 梅迪维新技术公司 桥连杂环化合物及其使用方法
AU2010298167B2 (en) 2009-09-23 2015-12-24 Medivation Technologies, Inc. Pyrido(3,4-b)indoles and methods of use
BR112012006640A2 (pt) 2009-09-23 2019-09-24 Medivation Technologies Inc composto, composição farmacêutica, método de tratamento de um distúrbio cognitivo, distúrbiopsocótico, distúrbio mediado por neurotransmissor ou um distúrbio neuronal e kit
US9034865B2 (en) 2010-02-18 2015-05-19 Medivation Technologies, Inc. Pyrido [4,3-B] indole and pyrido [3,4-B] indole derivatives and methods of use
US20130172320A1 (en) 2010-02-18 2013-07-04 Sarvajit Chakravarty Pyrido [4,3-b] indole and pyrido [3,4-b] indole derivatives and methods of use
WO2011103460A1 (en) 2010-02-18 2011-08-25 Medivation Technologies, Inc. Fused tetracyclic pyrido[4,3-b]indole and pyrido[3,4-b]ondole derivatives and methods of use
US9040519B2 (en) 2010-02-18 2015-05-26 Medivation Technologies, Inc. Fused tetracyclic pyrido [4,3-B] indole and pyrido [3,4-B] indole derivatives and methods of use
WO2011103448A1 (en) 2010-02-19 2011-08-25 Medivation Technologies, Inc. Methods and compositions for treating psychotic disorders using antipsychotic combination therapy
WO2011103430A1 (en) 2010-02-19 2011-08-25 Medivation Technologies, Inc. Pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use
EP2590647B1 (en) 2010-07-07 2017-11-08 Board of Regents of the University of Texas System Pro-neurogenic compounds
WO2012112963A1 (en) 2011-02-18 2012-08-23 Medivation Technologies, Inc. Compounds and methods for treatment of hypertension
WO2012112964A2 (en) 2011-02-18 2012-08-23 Medivation Technologies, Inc. PYRIDO[4,3-b]INDOLE AND PYRIDO[3,4-b]INDOLE DERIVATIVES AND METHODS OF USE
JP2014505737A (ja) 2011-02-18 2014-03-06 メディベイション テクノロジーズ， インコーポレイテッド 糖尿病を処置する化合物および方法
WO2012112965A1 (en) 2011-02-18 2012-08-23 Medivation Technologies, Inc. Compounds and methods of treating diabetes
WO2014031170A1 (en) 2012-08-22 2014-02-27 Medivation Technologies, Inc. Pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use
WO2014031165A1 (en) 2012-08-22 2014-02-27 Medivation Technologies, Inc. Compounds and methods of treating diabetes
AU2012388221B2 (en) 2012-08-24 2017-08-31 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020077318A1 (en) * 2000-09-20 2002-06-20 Frank Kristine E. Substituted azepino[4,5b] indoline derivatives

Also Published As

Publication number Publication date
US8569287B2 (en) 2013-10-29
US20140088087A1 (en) 2014-03-27
EP2348847A4 (en) 2012-05-23
AU2009308708A1 (en) 2010-05-06
CA2742322A1 (en) 2010-05-06
US9481676B2 (en) 2016-11-01
AR073924A1 (es) 2010-12-09
BRPI0921798A2 (pt) 2019-09-24
TW201022270A (en) 2010-06-16
AU2009308708B2 (en) 2015-11-19
HK1164641A1 (en) 2012-09-28
US20100152163A1 (en) 2010-06-17
US9409910B2 (en) 2016-08-09
US20140213577A1 (en) 2014-07-31
CN102316732B (zh) 2015-04-01
EP2348847A1 (en) 2011-08-03
JP2012507567A (ja) 2012-03-29
CN102316732A (zh) 2012-01-11
US20130190295A1 (en) 2013-07-25
JP5551708B2 (ja) 2014-07-16
WO2010051503A1 (en) 2010-05-06

Similar Documents

Publication Publication Date Title
TWI482773B (zh) 氮呯并〔４，５－ｂ〕吲哚及使用方法
TWI477503B (zh) 含有剛性部分之吡啶并〔４，３－ｂ〕吲哚
CN102480956B (zh) 吡啶并[4,3-b]吲哚类和使用方法
CN102480955B (zh) 吡啶并[4,3-b]吲哚类和使用方法
TWI450900B (zh) 橋聯雜環化合物及使用方法
CN102711467A (zh) 吡啶并[3,4-b]吲哚类及使用方法
CN102711466A (zh) 桥连杂环化合物及其使用方法
US20160030446A1 (en) Pyrido [4,3-b]indole and pyrido [3,4-b] indole derivatives and methods of use
WO2011103487A1 (en) Pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use
CN102711468A (zh) 吡啶并[4，3-b]吲哚化合物及其使用方法
WO2011014695A1 (en) New 2,3,4,5-tetrahydro-1h-pyrido[4,3-b] indoles and methods of use
HK1164641B (en) Azepino[4,5-b]indoles and methods of use
HK1176812A (en) Bridged heterocyclic compounds and methods of use
AU2013203575A1 (en) Pyrido [4,3-b] indoles and methods of use
HK1176814A (en) Pyrido[3,4-b]indoles and methods of use
HK1170380B (en) Pyrido [4,3-b] indoles and methods of use
AU2013203574A1 (en) Pyrido [4,3-b] indoles and methods of use
HK1176811B (en) Pyrido[4,3-b]indoles and methods of use

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees